Top Page
China Bozza Development Holdings Limited
(1069)
China Bozza Development Holdings Limited (1069) vs. iShares MSCI Hong Kong ETF (EWH)
China Bozza Development Holdings Limited Business Overview & Revenue Model
China Bozza Development Holdings Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2024 | Dec 2022 | Jun 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.60M | 97.39M | 47.61M | 58.72M | 6.76M | 6.67M |
| Gross Profit | 8.62M | 8.87M | 1.90M | 11.51M | 0.00 | 6.67M |
| EBITDA | -7.74M | -7.74M | 208.39M | -42.17M | -9.85M | -48.36M |
| Net Income | 24.03M | 24.52M | 200.01M | -10.80M | -18.90M | -268.54M |
Balance Sheet | ||||||
| Total Assets | 225.04M | 191.09M | 178.17M | 140.64M | 93.52M | 491.54M |
| Cash, Cash Equivalents and Short-Term Investments | 4.92M | 2.68M | 3.23M | 4.33M | 1.11M | 134.00K |
| Total Debt | 127.45M | 115.23M | 119.11M | 356.77M | 321.97M | 333.44M |
| Total Liabilities | 173.86M | 166.22M | 165.20M | 457.35M | 400.15M | 369.48M |
| Stockholders Equity | 51.18M | 24.87M | 12.96M | -316.71M | -306.63M | 122.06M |
Cash Flow | ||||||
| Free Cash Flow | 1.77M | -959.71K | 28.63M | 22.16M | -466.00K | -5.58M |
| Operating Cash Flow | 1.77M | 37.43M | 28.86M | 23.44M | -466.00K | -5.58M |
| Investing Cash Flow | -6.15M | -38.34M | -26.49M | -23.26M | 2.00K | -410.00K |
| Financing Cash Flow | 3.83M | 2.29M | -3.47M | 3.04M | -249.00K | -3.29M |
China Bozza Development Holdings Limited Technical Analysis
China Bozza Development Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$1.31B | 5.14 | 3.56% | 3.45% | -5.66% | -56.96% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
50 Neutral | HK$39.11M | 1.32 | 63.18% | ― | 88.72% | -91.59% | |
49 Neutral | HK$81.12M | -2.98 | 0.85% | ― | -5.06% | ― | |
46 Neutral | HK$6.98B | -0.27 | ― | ― | -76.55% | -966.54% | |
46 Neutral | HK$167.50M | 19.62 | 2.11% | 6.11% | 0.80% | 81.27% | |
45 Neutral | HK$233.41M | -1.62 | 0.19% | ― | -9.44% | ― |
China Bozza Development Holdings Limited Corporate Events
China Health Technology Group reported interim unaudited revenue of RMB34.4 million for the six months ended 31 December 2025, up from RMB31.1 million a year earlier, as gross profit rose to RMB4.1 million from RMB2.8 million. Profit for the period edged up to RMB5.3 million from RMB5.0 million, supported by stable other gains and lower administrative expenses, while finance costs increased and basic earnings per share declined on a restated basis.
Total comprehensive income slipped to RMB5.4 million from RMB6.4 million, mainly due to a smaller positive exchange translation effect compared with the previous period. The figures indicate modest top-line growth and resilient profitability despite higher financing costs, suggesting that the group is maintaining operational efficiency while facing currency fluctuations and capital cost pressure that stakeholders will need to monitor.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has scheduled a board meeting for 27 February 2026. The board will review and approve the Group’s interim results for the six months ended 31 December 2025 and consider whether to declare an interim dividend, signaling a forthcoming update on the company’s financial performance and potential shareholder returns.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has strengthened its leadership team with the appointment of Ms. Cao Xiying as an executive director effective 15 January 2026, bringing project management and sales and marketing experience from internet finance and media technology sectors; she will serve an initial one-year term with remuneration aligned to market levels. The company has also named Mr. Li Liangjie as an independent non-executive director, adding over 15 years of sales management expertise and nearly a decade of online marketing experience in the health and wellness industry, including his role at Henan Yuhuan Health Technology Group; these appointments are expected to enhance the board’s governance, marketing capabilities and sector-specific insight, while ensuring compliance with Hong Kong listing requirements on board and committee composition.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has announced the current composition of its board of directors and the allocation of roles across its key governance committees. Chairman and CEO Ms. Bu Xue serves as an executive director, alongside executive director Ms. Cao Xiying, while independent non-executive directors Mr. Chau Wing Nam, Ms. Liu Shuhua and Mr. Li Liangjie provide oversight, with Mr. Chau chairing the Audit, Remuneration and Nomination committees. The disclosure underscores the company’s emphasis on independent oversight and committee-based governance, a structure that may bolster investor confidence in its board independence and internal control framework.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has issued a supplemental announcement correcting clerical errors in the disclosed poll results for two ordinary resolutions at its 31 December 2025 annual general meeting, specifically those relating to authorising the board to fix directors’ remuneration and to re-appoint the company’s auditor, Jon Gepsom CPA Limited, and authorise the board to fix its remuneration; the corrected figures confirm both resolutions were passed with 100% of votes cast in favour. The company also rectified a mislabelled heading regarding changes in board committee composition, clarifying that it pertains to the composition of all board committees rather than only the nomination committee, while emphasising that all other information from the original announcement remains unchanged, thereby seeking to reassure investors about the accuracy of its governance disclosures.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
Shareholders of China Health Technology Group Holding Company Limited approved all resolutions at the 31 December 2025 annual general meeting, including adoption of the 2025 financial statements, director remuneration, reappointment of Jon Gepsom CPA Limited as auditor, and general mandates for the board to issue up to 20% and repurchase up to 10% of the company’s share capital, as well as an extension mandate and the adoption of a new share scheme. The results, all passed by poll with 100% support on votes cast, also confirmed board changes through the re-election or rejection of certain directors and signalled continued support for the company’s capital management flexibility and equity-based incentive arrangements, with implications for future share issuance and governance structure; the company simultaneously disclosed pending changes to the chairman role, board committees and a period of non-compliance with listing rules, underscoring ongoing governance adjustments closely watched by investors.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.
China Health Technology Group Holding Company Limited has announced the current composition of its board of directors, naming Ms. Bu Xue as executive director, chairman and chief executive officer, alongside independent non-executive directors Mr. Chau Wing Nam and Ms. Liu Shuhua. The company also clarified the structure and membership of its three main board committees, with Mr. Chau chairing the audit, remuneration and nomination committees, and Ms. Bu and Ms. Liu serving as members, underscoring the firm’s governance framework and the role of independent oversight in its board operations.
The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.